# Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

> **NCT03564938** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 100 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)

## Key facts

- **NCT ID:** NCT03564938
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-30
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-12-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564938, "Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03564938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*